Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
Central airway tumor invasion
drug-induced pneumonitis
immune checkpoint inhibitors
non-small cell lung cancer
risk factor
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
27
07
2020
revised:
27
09
2020
accepted:
28
09
2020
pubmed:
21
10
2020
medline:
20
11
2021
entrez:
20
10
2020
Statut:
ppublish
Résumé
Anti-programmed death-1 (PD-1) immunotherapy can cause immune-related pneumonitis, also known as checkpoint inhibitor pneumonitis (CIP). CIP that develops early after the initiation of anti-PD-1 immunotherapy is important because it is more severe than CIP that develops later. However, only a few studies have examined the risk factors for early-onset CIP. Previous studies have reported several risk factors for CIP, including imaging findings of airway obstruction adjacent to lung tumors. However, the utility of this factor is debatable. Therefore, we investigated potential risk factors for early-onset CIP, including tumor invasion in the central airway (TICA), in patients with non-small cell lung cancer (NSCLC) receiving anti-PD-1 therapy. We retrospectively analyzed the medical records and chest computed tomography scans of patients with NSCLC treated with anti-PD-1 antibodies at the Kanagawa Cancer Center in Japan between 1 January 2016, and 30 June 2018. The clinical characteristics and imaging findings, including TICA, were compared between patients with and without early-onset CIP. Data from 181 eligible patients (114 receiving nivolumab and 67 receiving pembrolizumab) were analyzed. Early-onset CIP occurred in 13 of 79 patients (16.5%) with TICA and 2 of 102 patients (2.0%) without TICA. In multivariate analysis, the odds ratio of early-onset CIP for patients with TICA was 8.2 (95% confidence interval [CI]: 1.98-34.0, P = 0.0037). TICA was strongly associated with early-onset CIP in patients with NSCLC. Clinicians should carefully observe patients with TICA, especially within three months of anti-PD-1 antibody administration because of high CIP risk. Significant study findings Tumor invasion in the central airway (TICA) was a predictor of early-onset checkpoint inhibitor pneumonitis (CIP) TICA had good interobserver variability, indicating its utility in clinical practice Patients with TICA might have a higher immune status than patients without What this study adds This is the first study focusing on risk factors for CIP limited to early-onset CIP.
Sections du résumé
BACKGROUND
Anti-programmed death-1 (PD-1) immunotherapy can cause immune-related pneumonitis, also known as checkpoint inhibitor pneumonitis (CIP). CIP that develops early after the initiation of anti-PD-1 immunotherapy is important because it is more severe than CIP that develops later. However, only a few studies have examined the risk factors for early-onset CIP. Previous studies have reported several risk factors for CIP, including imaging findings of airway obstruction adjacent to lung tumors. However, the utility of this factor is debatable. Therefore, we investigated potential risk factors for early-onset CIP, including tumor invasion in the central airway (TICA), in patients with non-small cell lung cancer (NSCLC) receiving anti-PD-1 therapy.
METHODS
We retrospectively analyzed the medical records and chest computed tomography scans of patients with NSCLC treated with anti-PD-1 antibodies at the Kanagawa Cancer Center in Japan between 1 January 2016, and 30 June 2018. The clinical characteristics and imaging findings, including TICA, were compared between patients with and without early-onset CIP.
RESULTS
Data from 181 eligible patients (114 receiving nivolumab and 67 receiving pembrolizumab) were analyzed. Early-onset CIP occurred in 13 of 79 patients (16.5%) with TICA and 2 of 102 patients (2.0%) without TICA. In multivariate analysis, the odds ratio of early-onset CIP for patients with TICA was 8.2 (95% confidence interval [CI]: 1.98-34.0, P = 0.0037).
CONCLUSIONS
TICA was strongly associated with early-onset CIP in patients with NSCLC. Clinicians should carefully observe patients with TICA, especially within three months of anti-PD-1 antibody administration because of high CIP risk.
KEY POINTS
Significant study findings Tumor invasion in the central airway (TICA) was a predictor of early-onset checkpoint inhibitor pneumonitis (CIP) TICA had good interobserver variability, indicating its utility in clinical practice Patients with TICA might have a higher immune status than patients without What this study adds This is the first study focusing on risk factors for CIP limited to early-onset CIP.
Identifiants
pubmed: 33078531
doi: 10.1111/1759-7714.13703
pmc: PMC7705619
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3576-3584Informations de copyright
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
JAMA Oncol. 2016 Oct 1;2(10):1346-1353
pubmed: 27367787
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Lung Cancer. 2018 Nov;125:150-156
pubmed: 30429014
J Immunol. 2011 Oct 1;187(7):3730-7
pubmed: 21873525
Chest. 2017 Aug;152(2):271-281
pubmed: 28499515
Future Oncol. 2019 Jun;15(16):1911-1920
pubmed: 31020849
N Engl J Med. 2010 Oct 14;363(16):1578-9; author reply 1579-80
pubmed: 20942679
J Thorac Oncol. 2018 Dec;13(12):1930-1939
pubmed: 30267842
Lung Cancer. 2018 Nov;125:212-217
pubmed: 30429022
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
Biol Chem. 2015 Nov;396(11):1181-97
pubmed: 26040008
Eur Respir J. 2017 Aug 10;50(2):
pubmed: 28798088
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Curr Opin Immunol. 2010 Jun;22(3):397-401
pubmed: 20427170
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Blood. 2009 Jun 4;113(23):5811-8
pubmed: 19339692
Thorac Cancer. 2018 Jul;9(7):847-855
pubmed: 29782069
Cancer Med. 2018 Aug;7(8):4115-4120
pubmed: 29797416
Lung Cancer. 2017 Feb;104:111-118
pubmed: 28212992
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
In Vivo. 2018 Jul-Aug;32(4):887-891
pubmed: 29936475
Oncoimmunology. 2017 Oct 26;7(2):e1386362
pubmed: 29308309
J Biomed Biotechnol. 2011;2011:451694
pubmed: 21960736
Cancer Immunol Res. 2018 Sep;6(9):1093-1099
pubmed: 29991499
Radiology. 2003 Aug;228(2):303-8
pubmed: 12819342